GlassScriptPhysician profile
George V Antonopoulos
NPI 1457419814
$12,806.66
in general payments reported to CMS, 2019-2025
19 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $335 · 2021: $320 · 2022: $368 · 2023: $247 · 2024: $1,158 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Travel and Lodging: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.95 |
| Travel and Lodging | $771.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,573.13 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $1,132.08 | 2024 | Venclose Maven Catheter, Rotarexs 6 F X 135 Cm |
| Abbott Laboratories | $894.59 | 2019-2025 | Aveir, Jot Dx, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $450.61 | 2019-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $147.59 | 2019-2022 | |
| Pfizer INC. | $133.61 | 2023-2025 | |
| Amgen INC. | $86.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.18 | 2019 | |
| Bardy Diagnostics, INC. | $66.49 | 2020 | |
| Boston Scientific Corporation | $46.36 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.80 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $33.04 | 2019 | |
| Novo Nordisk INC | $26.84 | 2025 | Wegovy |
| Heartflow, INC. | $26.12 | 2024 | |
| Amarin Pharma, INC. | $17.36 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $15.73 | 2019 | |
| Scpharmaceuticals INC. | $15.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $14.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Antonopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.